EI
BMY icon

Ethic Inc’s Bristol-Myers Squibb BMY Stock Holding History

Ethic Inc’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Buy
270,904
+39,266
+17% +$2.25M 0.19% 95
2026
Q1 		$14M Buy
231,638
+19,336
+9% +$1.13M 0.22% 86
2025
Q4 		$11.5M Buy
212,302
+8,347
+4% +$402K 0.18% 113
2025
Q3 		$9.2M Buy
203,955
+102,199
+100% +$4.77M 0.15% 139
2025
Q2 		$4.72M Sell
101,756
-12,281
-11% -$603K 0.08% 249
2025
Q1 		$6.79M Sell
114,037
-60,387
-35% -$3.52M 0.14% 165
2024
Q4 		$9.87M Buy
174,424
+6,044
+4% +$338K 0.2% 96
2024
Q3 		$9.13M Buy
168,380
+24,235
+17% +$1.14M 0.23% 87
2024
Q2 		$5.99M Sell
144,145
-24,235
-14% -$1.08M 0.14% 155
2024
Q1 		$9.13M Sell
168,380
-16,479
-9% -$839K 0.23% 87
2023
Q4 		$9.49M Buy
184,859
+9,174
+5% +$482K 0.28% 70
2023
Q3 		$10.2M Buy
175,685
+38,792
+28% +$2.38M 0.36% 46
2023
Q2 		$8.75M Buy
136,893
+15,369
+13% +$1.03M 0.32% 58
2023
Q1 		$8.42M Buy
121,524
+25,385
+26% +$1.79M 0.34% 55
2022
Q4 		$6.92M Buy
96,139
+13,788
+17% +$1.04M 0.37% 46
2022
Q3 		$5.85M Buy
82,351
+6,857
+9% +$497K 0.4% 43
2022
Q2 		$5.81M Buy
75,494
+21,758
+40% +$1.66M 0.41% 46
2022
Q1 		$3.92M Buy
53,736
+11,449
+27% +$769K 0.27% 88
2021
Q4 		$2.64M Buy
42,287
+17,038
+67% +$999K 0.2% 121
2021
Q3 		$1.49M Buy
25,249
+5,744
+29% +$378K 0.15% 173
2021
Q2 		$1.3M Buy
19,505
+3,638
+23% +$237K 0.16% 161
2021
Q1 		$1M Sell
15,867
-8,540
-35% -$531K 0.18% 155
2020
Q4 		$1.51M Buy
24,407
+7,214
+42% +$444K 0.4% 54
2020
Q3 		$1.04M Sell
17,193
-4,720
-22% -$284K 0.4% 52
2020
Q2 		$1.29M Buy
21,913
+5,885
+37% +$352K 0.73% 30
2020
Q1 		$893K Buy
16,028
+335
+2% +$20.5K 0.75% 29
2019
Q4 		$1.01M Buy
+15,693
New +$899K 0.74% 24

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ethic Inc's BMY Position: Q2 2026 in Review

Ethic Inc increased its Bristol-Myers Squibb (BMY) stake by 17% in Q2 2026, buying an estimated $2.25M and bringing the position to 270,904 shares worth $15.6M. The position accounts for 0.19% of the portfolio, ranked #95.

Ethic Inc first reported a position in BMY in Q4 2019 and has held it in 27 quarters since. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Ethic Inc held 270,904 shares of Bristol-Myers Squibb worth $15.6M as of Q2 2026.
  • Ethic Inc bought 39,266 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.25M.
  • Bristol-Myers Squibb made up 0.19% of Ethic Inc's portfolio in Q2 2026, its #95 holding.
  • Ethic Inc first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 27 quarters since.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.